Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole
affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharma-
codynamics. J Clin Pharmacol 1993b;33:1201–1206.
Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR.
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic
consequences. JAMA 1993c;269:1513–1518.
Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J,
Erdman K, Lyons N, Niu P, Decourt JP, Fourtillan JB, Girault J, Leonard JM.
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-
infected subjects. Antimicrob Agents Chemother 1997;41:898–905.
Ito K, Brown HS, Houston JB. Database analyses for the prediction ofin vivo
drug–drug interactions from in vitro data. Br J Clin Pharmacol 2004;57:473–
486.
Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of
in vivodrug clearance and drug interactions fromin vitrodata on metabolism,
together with binding and transport. Annu Rev Pharmacol Toxicol 1998a;38:461–
499.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of
pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction
in the liver. Pharmacol Rev 1998b;50:387–412.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of
pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction
in the liver. Pharmacol Rev 1998c;50:387–412.
Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation
of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit
extract. Drug Metab Pharmacokinet 2005;20:34–45.
Jenkins KM, Angeles R, Quintos MT, Xu R, Kassel DB, Rourick RA. Automated
high throughput ADME assays for metabolic stability and cytochrome P450
inhibition profiling of combinatorial libraries. J Pharm Biomed Anal 2004;34:989–
1004.
Jung MJ, Metcalf BW. Catalytic inhibition of gamma-aminobutyric acid - alpha-
ketoglutarate transaminase of bacterial origin by 4-aminohex-5-ynoic acid, a
substrate analog. Biochem Biophys Res Commun 1975;67:301–306.
Jushchyshyn MI, Kent UM, Hollenberg PF. The mechanism-based inactivation of
human cytochrome P450 2B6 by phencyclidine. Drug Metab Dispos 2003;31:46–
52.
Kanamitsu S, Ito K, Sugiyama Y. Quantitative prediction ofin vivo drug–drug
interactions fromin vitrodata based on physiological pharmacokinetics: use of
maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res
2000;17:336–343.
Kariv I, Fereshteh MP, Oldenburg KR. Development of a miniaturized 384-well high
throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4
metabolism. J Biomol Screen 2001;6:91–99.
Kennedy SW, Jones SP. Simultaneous measurement of cytochrome P4501A catalytic
activity and total protein concentration with a fluorescence plate reader. Anal
Biochem 1994;222:217–223.
REFERENCES 541